Drs. Margaret Greven from Wake Forest University and Ali Khan from the Doheny Eye Institute join the program to preview the April 2019 issue of Retinal Physician. They discuss wet and dry AMD topics including conbercept, vision loss in wet AMD and real world outcomes of injections, and the mitochondria as a drug target for dry AMD.
Relevant Financial Disclosures: Dr. Sridhar is a consultant for Alcon Laboratories. Dr. Greven is a consultant for Alimera Sciences. Dr. Khan is a consultant for Allergan.
CME Information
Release: Apr. 1, 2019; expires Apr. 1, 2022
Reviewers: Purnima Patel, MD; Shriji Patel, MD; Carl Danzig, MD
Disclosures: The physician reviewers and Academy staff report no relevant financial disclosures.
Learning Objective: Upon completion of this episode, the listener should be able to describe evolving standards of care for the management of vitreoretinal disorders or the outcomes from recent research and how these impact patient care decisions.
Audience: This activity is intended for retina subspecialists and comprehensive ophthalmologists.
Accreditation: The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Academy of Ophthalmology designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits.TM Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hardware/Software Requirements: This learning activity requires a current web browser and speaker or headset capable of playing streaming audio.